Being the Joint Bookrunner and Joint Lead Manager, ABCI successfully assisted Fosun Pharmaceutical (Stock code: 2196.HK) to get listed on the HKEx on October 30, 2012. The listing has raised a total of HK$3.97 billion and was the largest IPO in Hong Kong for last 3 months. Fosun Pharmaceutical has now become an A+H shares listed company.

Fosun Pharmaceutical, listed on Shanghai Stock Exchange in 1998, is a subsidiary of Fosun International and one of the top 10 largest local pharmaceutical companies in China. Its main business includes pharmaceutical business, pharmaceutical distribution and retail, healthcare services, and diagnostic products and medical devices. Fosun Pharmaceutical is the second largest shareholder of Sinopharm, China's largest pharmaceutical distributor.